Divestiture of Three Pediatric Drugs to Concordia Pharmaceuticals
Concordia Pharmaceuticals Inc. acquired the rights to three Shionogi Inc. products: Kapvay™, Orapred ODT®, and Orapred® OS. As part of the agreement Shionogi will provide transition services to Concordia. This divestiture allowed Shionogi put more focus and resources on those products that are strategically core to its operations, and to progress development of products in its pipeline. Shionogi Inc. is the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Osaka, Japan. Shionogi is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi Inc. is focused primarily on two therapeutic areas in the U.S.: women’s health and pain. In addition, Shionogi is engaged in new research in areas such as allergy and cancer.